Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Uncertainty: Confidence Intervals00:54

Uncertainty: Confidence Intervals

The confidence interval is the range of values around the mean that contains the true mean. It is expressed as a probability percentage. The interpretation of a 95% confidence interval, for instance, is that the statistician is 95% confident that the true mean falls within the interval. The upper and lower limits of this range are known as confidence limits. The confidence limits for the true mean are estimated from the sample's mean, the standard deviation, and the statistical factor 't,' or...
Uncertainty: Overview00:59

Uncertainty: Overview

In analytical chemistry, we often perform repetitive measurements to detect and minimize inaccuracies caused by both determinate and indeterminate errors. Despite the cares we take, the presence of random errors means that repeated measurements almost never have exactly the same magnitude. The collective difference between these measurements - observed values - and the estimated or expected value is called uncertainty. Uncertainty is conventionally written after the estimated or expected value.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing hospital practice from clinical failings to clinical excellence.

BMJ (Clinical research ed.)·2026
Same author

Whistleblowers: the NHS is still shooting the messenger.

BMJ (Clinical research ed.)·2022
Same author

Successful use of "Choice Architecture" and "Nudge Theory" in a quality improvement initiative of analgesia administration after Caesarean section.

Journal of evaluation in clinical practice·2018
Same author

Clinical engagement: a new concept or common sense all round?

Australian health review : a publication of the Australian Hospital Association·2018
Same author

Perioperative β blockade.

BMJ (Clinical research ed.)·2013
Same author

Whistleblowing and patient safety: the patient's or the profession's interests at stake?

Journal of the Royal Society of Medicine·2011
Same journal

The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Comparative landscape of artificial intelligence-assisted systematic literature reviews.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

TENS in chronic pain management: a 11-year nationwide analysis using the French National Health Data System.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Economic burden of breast cancer in Cyprus from a societal perspective.

Expert review of pharmacoeconomics & outcomes research·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Risk 2005 conference

Stephen Bolsin1

  • 1The Geelong Hospital, Ryrie Street, Geelong, Victoria 3220, Australia. steveb@barwonhealth.org.au

Expert Review of Pharmacoeconomics & Outcomes Research
|October 8, 2009
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: Jun 19, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022